Introduction
Recigarum is an innovative medicine developed by the Adamed laboratory that has been launched in Spain to help people stop smoking. This drug expands the pharmacological options available in Spanish pharmacies and has the support of the Ministry of Health, which has established conditions for its financing.
Active ingredient and presentation
The active ingredient in Recigarum is cytisinicline, formerly known as cytisine. This substance has been used for more than 40 years in Eastern European countries to help in the smoking cessation process. Recigarum comes in the form of 1.5 mg tablets, with a treatment period of 25 days. The consumption pattern is descending, starting with 6 tablets daily and gradually reducing the dose until reaching one at the end of the treatment.
Benefits and adherence
Recigarum stands out for its calendared blister presentation, which facilitates adherence to treatment. In addition, the Adamed laboratory has developed a WhatsApp chatbox to provide support to patients, answer questions and remind them about taking the medication. These measures seek to maximize the effectiveness of treatment and help smokers achieve their goal of quitting smoking.
Financing and conditions
Recigarum is supported by the National Health System (SNS) and its financing is subject to certain conditions established by the Ministry of Health. To access reimbursement from the SNS, smokers must consume a minimum of ten cigarettes a day and have a high physical dependence on tobacco. Additionally, treatment is limited to a single quit attempt per year.
Opinions and recommendations
Recigarum has generated positive expectations in the medical and scientific field. According to comparative studies, this medication has been shown to double the chances of success compared to placebo. In addition, it has been observed to have similar efficacy to other smoking cessation treatments. Adverse effects are mild and transient, and are not usually a reason for discontinuing treatment.
Conclusions
Recigarum represents a new pharmacological option for people who want to quit smoking. Its active ingredient, cytisinicline, has been shown to be effective in clinical studies and its presentation in a scheduled blister facilitates adherence to treatment. With the support of the Ministry of Health and financing from the SNS, this medicine is positioned as an important tool in the fight against smoking.
